These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease. Chang HY; Lin CC; Chao CJ; Lin YC; Wang YC; Liao CT; Huang JL; Lee YH; Huang CY; Chien LN; Hsu CY Mayo Clin Proc; 2023 Jan; 98(1):88-99. PubMed ID: 36109207 [TBL] [Abstract][Full Text] [Related]
3. Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure. Arfsten H; Goliasch G; Bartko PE; Prausmüller S; Spinka G; Cho A; Novak J; Haslacher H; Strunk G; Struck J; Hülsmann M; Pavo N Br J Clin Pharmacol; 2021 Mar; 87(3):916-924. PubMed ID: 32598074 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. Docherty KF; McMurray JJV Int J Cardiol; 2019 Apr; 281():179-185. PubMed ID: 29891240 [TBL] [Abstract][Full Text] [Related]
5. Long-term impact of angiotensin receptor-neprilysin inhibitor based on short-term treatment response in heart failure. Park HK; Park JS; Kim MS; Lee E; Choi H; Park YJ; Park BE; Kim HN; Kim N; Bae MH; Lee JH; Park HS; Cho Y; Jang SY; Yang DH ESC Heart Fail; 2023 Dec; 10(6):3430-3437. PubMed ID: 37705397 [TBL] [Abstract][Full Text] [Related]
6. Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system. Kim BJ; Huang CW; Chung J; Neyer JR; Liang B; Yu AS; Kwong EK; Park JS; Hung P; Sim JJ J Manag Care Spec Pharm; 2022 Oct; 28(10):1173-1179. PubMed ID: 36125061 [No Abstract] [Full Text] [Related]
7. Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction. Lee YC; Lin JK; Ko D; Cheng S; Patorno E; Glynn RJ; Tsacogianis T; Kim DH J Am Geriatr Soc; 2023 Oct; 71(10):3110-3121. PubMed ID: 37345734 [TBL] [Abstract][Full Text] [Related]
8. Angiotensin-Neprilysin Inhibition as a Paradigm for All? Vaduganathan M; Desai AS Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488 [TBL] [Abstract][Full Text] [Related]
9. Angiotensin Receptor Neprilysin Inhibitor Use and Blood Pressure Lowering in Patients With Heart Failure With Reduced Ejection Fraction Across the Spectrum of Kidney Function: An Analysis of the Veterans Administrative Health System. Gjyriqi G; York M; Abuazzam F; Herzog CA; Bangalore S; Lo KB; Sidhu MS; Vaduganathan M; Rangaswami J; Mathew RO J Card Fail; 2023 Mar; 29(3):258-268. PubMed ID: 36516938 [TBL] [Abstract][Full Text] [Related]
10. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Martin N; Manoharan K; Davies C; Lumbers RT Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072 [TBL] [Abstract][Full Text] [Related]
11. Angiotensin Receptor-Neprilysin Inhibition in Heart Failure With Reduced Ejection Fraction: A Paradigm for All? Konstam MA JACC Heart Fail; 2016 Oct; 4(10):823-825. PubMed ID: 27614938 [No Abstract] [Full Text] [Related]
12. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy. Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551 [TBL] [Abstract][Full Text] [Related]
13. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
14. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention? Abdelhamid M; Rosano G; Metra M; Adamopoulos S; Böhm M; Chioncel O; Filippatos G; Jankowska EA; Lopatin Y; Lund L; Milicic D; Moura B; Ben Gal T; Ristic A; Rakisheva A; Savarese G; Mullens W; Piepoli M; Bayes-Genis A; Thum T; Anker SD; Seferovic P; Coats AJS Eur J Heart Fail; 2022 Sep; 24(9):1460-1466. PubMed ID: 35753058 [TBL] [Abstract][Full Text] [Related]
15. Impact of angiotensin receptor-neprilysin inhibition on vascular function in heart failure with reduced ejection fraction: A pilot study. Nathaniel S; McGinty S; Witman MAH; Edwards DG; Farquhar WB; Hosmane V; Wenner MM Physiol Rep; 2022 Mar; 10(5):e15209. PubMed ID: 35246960 [TBL] [Abstract][Full Text] [Related]
16. Angiotensin receptor neprilysin inhibitor use in patients with left ventricular assist devices: A single-center experience. Alishetti S; Braghieri L; Jennings DL; Uriel N; Colombo PC; Yuzefpolskaya M Int J Artif Organs; 2022 Jan; 45(1):118-120. PubMed ID: 33467950 [TBL] [Abstract][Full Text] [Related]